Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dr Kurt Wolff GmbH & Co. Kg operates a company patent portfolio centered on the Biotechnology & Pharmaceuticals technology area. At present, the portfolio includes 5 pending office actions. These actions are spread across 5 distinct examiners, meaning that no two pending actions are currently being reviewed by the same individual. This one to one ratio between actions and examiners indicates a highly diversified prosecution landscape for the company.
The workload is further distributed across 5 distinct art units, matching the number of pending office actions and examiners. The busiest examiner, ZHANG SPIERING, DONGXIU, is responsible for 1 busiest examiner pending office action. In this specific portfolio, the busiest examiner designation is shared among all participants, as each of the 5 distinct examiners holds exactly one pending action.
Practitioners should recognize that this 5 to 5 to 5 alignment across actions, examiners, and art units prevents any single examiner's habits from dominating the portfolio's overall progress. Each of the 5 pending office actions must be navigated according to the specific requirements of a different art unit. This structure requires a versatile approach to prosecution, as the company must address the unique feedback of 5 different USPTO officials simultaneously.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KHAN, AMINA S | 1 | 47.6% | +43.0% |
| ZHANG SPIERING, DONGXIU | 1 | 41.2% | +65.2% |
| MEYERS, ELIZABETH ANNE | 1 | 22.2% | +93.3% |
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
| OLSEN, KAELEIGH ELIZABETH | 1 | 47.1% | +64.3% |
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246405 | HYDROXYAPATITE COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A VIRUS INFECTION | MEYERS, ELIZABETH ANNE | 85d |
| 17782566 | DEEP-LAYER REMINERALIZATION OF HYDROXYLAPATITE | SCOTLAND, REBECCA LYNN | 85d |
| 19114001 | AGENT FOR REPIGMENTATION OF KERATIN FIBERS, IN PARTICULAR HUMAN HAIR | KHAN, AMINA S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17918532 | O/W EMULSION CONTAINING ETHANOL | OLSEN, KAELEIGH ELIZABETH | 80d overdue |
| 18246405 | HYDROXYAPATITE COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A VIRUS INFECTION | MEYERS, ELIZABETH ANNE | 85d |
| 19114001 | AGENT FOR REPIGMENTATION OF KERATIN FIBERS, IN PARTICULAR HUMAN HAIR | KHAN, AMINA S | — |
| 18247527 | Composition for Treating Hair and Skin | ZHANG SPIERING, DONGXIU | — |
| 17919955 | TREATMENT REGIMEN WITH MINOXIDIL AND CAFFEINE | CHANG, KYUNG SOOK | — |
| Art Unit | Apps |
|---|---|
| 1764 | 1 |
| 1616 | 1 |
| 1617 | 1 |
| 1613 | 1 |
| 1619 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19114001 | AGENT FOR REPIGMENTATION OF KERATIN FIBERS, IN PARTICULAR HUMAN HAIR | KHAN, AMINA S | 1764 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 21, 2025 |
| 18247527 | Composition for Treating Hair and Skin | ZHANG SPIERING, DONGXIU | 1616 | §103Other | Non-Final OA | — | Pending | Mar 31, 2023 |
| 18246405 | HYDROXYAPATITE COMPOSITION FOR TREATMENT AND/OR PREVENTION OF A VIRUS INFECTION | MEYERS, ELIZABETH ANNE | 1617 | §103DP | Final Rejection | 85d | Pending | Mar 23, 2023 |
| 17919955 | TREATMENT REGIMEN WITH MINOXIDIL AND CAFFEINE | CHANG, KYUNG SOOK | 1613 | §103 | Final Rejection | — | Pending | Oct 19, 2022 |
| 17918532 | O/W EMULSION CONTAINING ETHANOL | OLSEN, KAELEIGH ELIZABETH | 1619 | §103 | Final Rejection | 80d overdue | Pending | Oct 12, 2022 |
| 17782566 | DEEP-LAYER REMINERALIZATION OF HYDROXYLAPATITE | SCOTLAND, REBECCA LYNN | 1615 | §103§112 | Final Rejection | 85d | Pending | Jun 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDr Kurt Wolff GmbH & Co. Kg has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Amina S Khan has the most, with 1 of Dr Kurt Wolff GmbH & Co. Kg's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
